Voting Rights and Shares Capital of the Company
NanoBioTix (Nasdaq: NBTX) provided its voting rights and share capital update dated October 15, 2025. The company reports 48,237,471 shares outstanding (as of September 30, 2025) and a total theoretical number of voting rights of 50,318,257 with 50,296,139 exercisable voting rights. Markets: Euronext Paris (Compartment B) and NasdaqEuronext. ISIN: FR0011341205. This notice fulfills disclosure requirements under French commercial and AMF rules regarding the number of shares and voting rights.
NanoBioTix (Nasdaq: NBTX) ha fornito il suo aggiornamento sui diritti di voto e sul capitale sociale datato 15 ottobre 2025. L'azienda riporta 48,237,471 azioni in circolazione (al 30 settembre 2025) e un numero teorico totale di diritti di voto di 50,318,257 con 50,296,139 diritti di voto esercitabili. Mercati: Euronext Paris (Compartment B) e NasdaqEuronext. ISIN: FR0011341205. Questo avviso soddisfa i requisiti di informativa previsti dalla normativa commerciale francese e dall'AMF riguardo al numero di azioni e ai diritti di voto.
NanoBioTix (Nasdaq: NBTX) presentó su actualización de derechos de voto y capital social con fecha 15 de octubre de 2025. La empresa informa 48,237,471 acciones en circulación (al 30 de septiembre de 2025) y un número teórico total de derechos de voto de 50,318,257 con 50,296,139 derechos de voto ejercitables. Mercados: Euronext Paris (Compartment B) y NasdaqEuronext. ISIN: FR0011341205. Este aviso cumple con los requisitos de divulgación conforme a la normativa francesa y a las reglas de la AMF sobre el número de acciones y derechos de voto.
NanoBioTix (나스닥: NBTX)는 날짜가 2025년 10월 15일인 의결권 및 자본 업데이트를 제공했습니다. 회사는 48,237,471 주의 발행주식 수(2025년 9월 30일 기준)와 50,318,257의 이론상 의결권 총수, 50,296,139의 행사 가능한 의결권을 보고합니다. markets: Euronext Paris (Compartment B) 및 NasdaqEuronext. ISIN: FR0011341205. 이 공지는 주식 수 및 의결권에 관한 프랑스 상법 및 AMF 규정에 따른 공시 요건을 충족합니다.
NanoBioTix (Nasdaq: NBTX) a fourni sa mise à jour des droits de vote et du capital social datée du 15 octobre 2025. L'entreprise déclare 48 237 471 actions en circulation (au 30 septembre 2025) et un nombre théorique total de droits de vote de 50 318 257 avec 50 296 139 droits de vote exerçables. Marchés : Euronext Paris (Compartment B) et NasdaqEuronext. ISIN : FR0011341205. Cet avis remplit les exigences de divulgation en vertu du droit commercial français et des règles de l'AMF concernant le nombre d'actions et les droits de vote.
NanoBioTix (Nasdaq: NBTX) hat sein Update zu Stimmrechten und Kapital zum Datum 15. Oktober 2025 vorgelegt. Das Unternehmen meldet 48.237.471 ausstehende Aktien (Stand 30. September 2025) und eine theoretische Gesamtzahl an Stimmrechten von 50.318.257 mit 50.296.139 ausübbaren Stimmrechten. Märkte: Euronext Paris (Compartment B) und NasdaqEuronext. ISIN: FR0011341205. Diese Mitteilung erfüllt die Offenlegungspflichten gemäß französischem Handelsrecht und AMF-Regeln hinsichtlich der Anzahl der Aktien und der Stimmrechte.
NanoBioTix (ناسداك: NBTX) قدمت تحديث حقوق التصويت ورأس المال بتاريخ 15 أكتوبر 2025. الشركة تقرّ 48,237,471 سهماً قائماً (حتى 30 سبتمبر 2025) ونِـs 50,318,257 عدد افتراضي إجمالي من حقوق التصويت مع 50,296,139 حقوق تصويت قابلة للتعيين. الأسواق: Euronext Paris (Compartment B) و NasdaqEuronext. ISIN: FR0011341205. هذا الإشعار يفي بمتطلبات الإفصاح وفقاً للقوانين التجارية الفرنسية وقواعد AMF فيما يتعلق بعدد الأسهم وحقوق التصويت.
NanoBioTix（纳斯达克：NBTX） 提供了其投票权及股本更新，日期为 2025年10月15日。公司报告 48,237,471 股在外流通股（截至 2025 年 9 月 30 日）以及理论投票权总数为 50,318,257，可行使的投票权为 50,296,139。市场：巴黎泛欧交易所（B 组）和 NasdaqEuronext。ISIN：FR0011341205。本通知符合法国商业法及 AMF 关于股数与投票权的披露要求。
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| September 30, 2025 | 48,237,471 | 50,318,257 | 50,296,139 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
__________________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2025-10-15 -- NBTX -- Voting Rights & Shares Capital -- FINAL
FAQ
How many shares outstanding does NanoBioTix (NBTX) report as of September 30, 2025?
What are the total voting rights for NanoBioTix (NBTX) reported on October 15, 2025?
Which markets and ISIN are listed for NanoBioTix (NBTX) in the October 15, 2025 notice?
Why did NanoBioTix publish a voting rights update on October 15, 2025?
Where can investors find NanoBioTix (NBTX) voting rights information?
